Company Profile
Dermata Therapeutics Stock Price, News & Catalysts
- Ticker:
- DRMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.53 USD (-1.50%)
Close
Last updated: November 19, 2026
5.47M USD
Market cap
Why the stock is moving
Following the latest company update, “Dermata Announces U.S. Trademark Registration for TOME(R)”, DRMA closed down 5.26% at $0.5401 on Nov 18, 2026. The move occurred in the trading session associated with this commercial update.
Company overview
Consumer Skincare Company
Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
Tome Brand
Tome is designed as a professional-style at-home skincare line built around simplified, periodic treatments rather than multi-step daily regimens.
Foundational Treatment
The first product is a once-weekly mask intended to support skin renewal and serve as the foundation of the broader Tome portfolio.
Commercial Skincare Transition
Dermata has shifted from a development-stage pharmaceutical model to a direct-to-consumer skincare business built around its Bioneedle ingredient and the Tome product line.
Future catalysts
- Commercial launch of Tome Clearing Treatment for acne in the first half of 2027, subject to successful development.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Dermata Therapeutics (DRMA)?
Dermata Therapeutics (DRMA) most recently closed at 0.53 USD, a -1.50% move versus the previous session.
What is the market cap of Dermata Therapeutics (DRMA)?
Dermata Therapeutics currently has a market capitalization of 5.47M USD on BioPharmSignal.
What does Dermata Therapeutics do?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy. Tome Brand Tome is designed as a professional-style at-home skincare line built around simplified, periodic treatments rather than multi-step daily regimens. Foundational Treatment The first product...
On which exchange is DRMA stock listed?
Dermata Therapeutics (DRMA) is associated with NASDAQ, United States, Biopharma.
What is Consumer?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
Which conditions is Dermata Therapeutics targeting with Consumer?
Dermata Therapeutics is associated with dermatology based on its company overview and current catalyst commentary.
How does Dermata Therapeutics describe recent progress with Consumer?
Commercial launch of Tome Clearing Treatment for acne in the first half of 2027, subject to successful development.
What is Skincare?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
